CHMFL-EGFR-202 | EGFR Mutant Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / CHMFL-EGFR-202

CHMFL-EGFR-202 {[allProObj[0].p_purity_real_show]}

货号：A958784

CHMFL-EGFR-202 can form a covalent bond with Cys797 in a distinct "DFG-in-C-Helix-out" inactive EGFR conformation.

CHMFL-EGFR-202 化学结构
CAS号：2089381-40-6

CHMFL-EGFR-202 3D分子结构
CAS号：2089381-40-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

CHMFL-EGFR-202 纯度/质量文件产品仅供科研

货号：A958784 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

EGFR 亚型比较
MEK 亚型比较
BTK 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750), IC50: 2 nM EGFR (E746_A750/T790M), IC50: 14 nM						{[allProObj[0].p_purity_real_show]}
Daphnetin	+ EGFR, IC50: 7.67 μM					PKC,PKA	{[allProObj[0].p_purity_real_show]}
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		{[allProObj[0].p_purity_real_show]}
PD168393	++++ EGFR, IC50: 0.70 nM						{[allProObj[0].p_purity_real_show]}
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		{[allProObj[0].p_purity_real_show]}
Norcantharidin	✔						{[allProObj[0].p_purity_real_show]}
CL-387785	++++ EGFR, IC50: 370 pM						{[allProObj[0].p_purity_real_show]}
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	{[allProObj[0].p_purity_real_show]}
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	{[allProObj[0].p_purity_real_show]}
AG 555	+ EGFR, IC50: 0.7 μM						{[allProObj[0].p_purity_real_show]}
AG 494	+ EGFR, IC50: 1.2 μM						{[allProObj[0].p_purity_real_show]}
AG-556	+ EGFR, IC50: 5 μM						{[allProObj[0].p_purity_real_show]}
RG13022	+ EGFR, IC50: 4 μM						{[allProObj[0].p_purity_real_show]}
Tyrphostin RG 14620	✔						{[allProObj[0].p_purity_real_show]}
Vandetanib	+ EGFR, IC50: 500 nM						{[allProObj[0].p_purity_real_show]}
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		{[allProObj[0].p_purity_real_show]}
AZD3759	++++ EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM						{[allProObj[0].p_purity_real_show]}
Erlotinib	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Saracatinib	+++ EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
AG1557	✔						{[allProObj[0].p_purity_real_show]}
Rociletinib	++ EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM						{[allProObj[0].p_purity_real_show]}
AG490	+ EGFR, IC50: 0.1 μM						{[allProObj[0].p_purity_real_show]}
Cetuximab	++++ EGFR, Kd: 0.39 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib	++ WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Chrysophanol	✔					mTOR	{[allProObj[0].p_purity_real_show]}
PD153035	++++ EGFR, Ki: 5.2 pM						{[allProObj[0].p_purity_real_show]}
Olmutinib	✔					BTK	{[allProObj[0].p_purity_real_show]}
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						{[allProObj[0].p_purity_real_show]}
Icotinib	+++ EGFR, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Cyasterone	✔						{[allProObj[0].p_purity_real_show]}
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						{[allProObj[0].p_purity_real_show]}
WZ8040	✔						{[allProObj[0].p_purity_real_show]}
(-)-Epigallocatechin Gallate	✔						{[allProObj[0].p_purity_real_show]}
AG 18	+ EGFR, IC50: 35 μM						{[allProObj[0].p_purity_real_show]}
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						{[allProObj[0].p_purity_real_show]}
Falnidamol	✔						{[allProObj[0].p_purity_real_show]}
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	{[allProObj[0].p_purity_real_show]}
Butein	✔						{[allProObj[0].p_purity_real_show]}
Genistein	✔						{[allProObj[0].p_purity_real_show]}
SU5214	+ EGFR, IC50: 36.7 μM						{[allProObj[0].p_purity_real_show]}
Naquotinib	✔						{[allProObj[0].p_purity_real_show]}
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		{[allProObj[0].p_purity_real_show]}
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		{[allProObj[0].p_purity_real_show]}
Lazertinib	++++ WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM				++++ Del19/T790M, IC50: 1.7 nM		{[allProObj[0].p_purity_real_show]}
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						{[allProObj[0].p_purity_real_show]}
MTX-211	✔					PI3K	{[allProObj[0].p_purity_real_show]}
(E)-AG 99	✔						{[allProObj[0].p_purity_real_show]}
Licochalcone D	✔					Caspase,PARP	{[allProObj[0].p_purity_real_show]}
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		{[allProObj[0].p_purity_real_show]}
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		{[allProObj[0].p_purity_real_show]}
Firmonertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Tyrphostin AG30	✔						{[allProObj[0].p_purity_real_show]}
EGFR-IN-12	++ EGFR, IC50: 21 nM						{[allProObj[0].p_purity_real_show]}
Mobocertinib	✔						{[allProObj[0].p_purity_real_show]}
(Rac)-JBJ-04-125-02	✔						{[allProObj[0].p_purity_real_show]}
(S)-Sunvozertinib	✔						{[allProObj[0].p_purity_real_show]}
BLU-945	✔						{[allProObj[0].p_purity_real_show]}
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			{[allProObj[0].p_purity_real_show]}
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			{[allProObj[0].p_purity_real_show]}
ARRY-380 analog				✔			{[allProObj[0].p_purity_real_show]}
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			{[allProObj[0].p_purity_real_show]}
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			{[allProObj[0].p_purity_real_show]}
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			{[allProObj[0].p_purity_real_show]}
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			{[allProObj[0].p_purity_real_show]}
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			{[allProObj[0].p_purity_real_show]}
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms	{[allProObj[0].p_purity_real_show]}
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^T790M, IC50: 0.79 nM EGFR^L858R/T790M, IC50: 0.51 nM		{[allProObj[0].p_purity_real_show]}
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	{[allProObj[0].p_purity_real_show]}
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			{[allProObj[0].p_purity_real_show]}
Tucatinib				+++ ErbB2, IC50: 8 nM			{[allProObj[0].p_purity_real_show]}
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Raf,Src	{[allProObj[0].p_purity_real_show]}
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			{[allProObj[0].p_purity_real_show]}
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	{[allProObj[0].p_purity_real_show]}
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			{[allProObj[0].p_purity_real_show]}
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Canertinib dihydrochloride	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			{[allProObj[0].p_purity_real_show]}
Allitinib tosylate	++++ EGFR, IC50: 0.5 nM EGFR (T790M/L858R), IC50: 12 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			{[allProObj[0].p_purity_real_show]}
Afatinib	++++ EGFR (L858R), IC50: 10 nM EGFR (wt), IC50: 0.5 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			{[allProObj[0].p_purity_real_show]}
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			{[allProObj[0].p_purity_real_show]}
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			{[allProObj[0].p_purity_real_show]}
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	{[allProObj[0].p_purity_real_show]}
Brigatinib					+ EGFR(del19), IC50: 39.9 nM EGFR(C797S/T790M/del19), IC50: 67.2 nM	ALK,FLT3	{[allProObj[0].p_purity_real_show]}
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	{[allProObj[0].p_purity_real_show]}
EAI045					✔		{[allProObj[0].p_purity_real_show]}
Almonertinib					✔		{[allProObj[0].p_purity_real_show]}
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		{[allProObj[0].p_purity_real_show]}
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	MEK ↓ ↑	MEK1 ↓ ↑	MEK1/2 ↓ ↑	MEK2 ↓ ↑	MEK5 ↓ ↑	其他靶点	纯度
Honokiol	✔						{[allProObj[0].p_purity_real_show]}
Mirdametinib	++++ MEK, IC50: 0.33 nM						{[allProObj[0].p_purity_real_show]}
Binimetinib	+++ MEK, IC50: 12 nM						{[allProObj[0].p_purity_real_show]}
BI-847325		++ MEK1, IC50: 25 nM		+++ MEK2, IC50: 4 nM			{[allProObj[0].p_purity_real_show]}
U0126-EtOH		+ MEK1, IC50: 0.07 μM		++ MEK2, IC50: 0.06 μM			{[allProObj[0].p_purity_real_show]}
GDC-0623		++++ MEK1, IC50: 0.13 nM					{[allProObj[0].p_purity_real_show]}
TAK-733		++++ MEK1, IC50: 3.2 nM					{[allProObj[0].p_purity_real_show]}
Trametinib		++++ MEK1, IC50: 0.92 nM		++++ MEK2, IC50: 1.8 nM			{[allProObj[0].p_purity_real_show]}
Selumetinib		+++ MEK1, IC50: 14 nM MEK1, Kd: 99 nM		+ MEK2, Kd: 530 nM			{[allProObj[0].p_purity_real_show]}
CI-1040		++ MEK1, IC50: 17 nM		++ MEK2, IC50: 17 nM			{[allProObj[0].p_purity_real_show]}
Myricetin		✔					{[allProObj[0].p_purity_real_show]}
Refametinib		++ MEK1, IC50: 19 nM		++ MEK2, IC50: 47 nM			{[allProObj[0].p_purity_real_show]}
Cobimetinib		+++ MEK1, IC50: 4.2 nM					{[allProObj[0].p_purity_real_show]}
PD98059		+ MEK1, IC50: 2 μM					{[allProObj[0].p_purity_real_show]}
SL327		+ MEK1, IC50: 0.18 μM		+ MEK2, IC50: 0.22 μM		AP-1	{[allProObj[0].p_purity_real_show]}
PD318088			✔				{[allProObj[0].p_purity_real_show]}
AZD8330			+++ MEK1/2, IC50: 7 nM				{[allProObj[0].p_purity_real_show]}
Pimasertib							{[allProObj[0].p_purity_real_show]}
(E/Z)-BIX02189					++++ MEK5, IC50: 1.5 nM		{[allProObj[0].p_purity_real_show]}
(E/Z)-BIX02188					+++ MEK5, IC50: 4.3 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	BTK ↓ ↑	纯度
CGI-1746	+++ BTK, IC50: 1.9 nM	{[allProObj[0].p_purity_real_show]}
Spebrutinib	++++ BTK, IC50: <0.5 nM	{[allProObj[0].p_purity_real_show]}
Acalabrutinib	++ BTK, IC50: 3nM	{[allProObj[0].p_purity_real_show]}
CNX-774	+++ BTK, IC50: <1 nM	{[allProObj[0].p_purity_real_show]}
Ibrutinib	++++ BTK, IC50: 0.5 nM	{[allProObj[0].p_purity_real_show]}
ONO-4059 analog	+ BTK, IC50: 23.9 nM	{[allProObj[0].p_purity_real_show]}
RN486	++ BTK, IC50: 4 nM	{[allProObj[0].p_purity_real_show]}
(Z)-LFM-A13	+ BTK, Ki: 1.4 μM	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

CHMFL-EGFR-202 生物活性

描述	CHMFL-EGFR-202 can form a covalent bond with Cys797 in a distinct "DFG-in-C-Helix-out" inactive EGFR conformation.

CHMFL-EGFR-202 参考文献

[1]Wang A, Li X, et al. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

CHMFL-EGFR-202 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.20mL

2.04mL

1.02mL

20.41mL

4.08mL

2.04mL

CHMFL-EGFR-202 技术信息

CAS号	2089381-40-6
分子式	C₂₅H₂₄ClN₇O₂
分子量	489.957

别名
运输	蓝冰

存储条件

粉末

液体 -20°C:3-6个月-80°C:12个月

溶解度

动物实验配方

CHMFL-EGFR-202 {[allProObj[0].p_purity_real_show]}

CHMFL-EGFR-202 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

CHMFL-EGFR-202 质控信息

CHMFL-EGFR-202 生物活性

CHMFL-EGFR-202 参考文献

CHMFL-EGFR-202 实验方案

CHMFL-EGFR-202 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

CHMFL-EGFR-202 {[allProObj[0].p_purity_real_show]}

CHMFL-EGFR-202 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

CHMFL-EGFR-202 质控信息

CHMFL-EGFR-202 生物活性

CHMFL-EGFR-202 参考文献

CHMFL-EGFR-202 实验方案

CHMFL-EGFR-202 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

CHMFL-EGFR-202 纯度/质量文件产品仅供科研